What TF Capital does

TF Capital (泰福资本) is a Shanghai-headquartered, dual-currency venture capital firm founded in 2014 that specializes in early-stage biotechnology and pharmaceutical investments in China. The firm operates as the "first and most significant money" investor for innovative biotech companies, providing capital alongside strategic expertise and leveraging proprietary deal sourcing through deep biopharmaceutical industrial networks and exclusive founder relationships. TF Capital invests across oncology, immunology, neuroscience, metabolic diseases, ophthalmology, and emerging modalities including RNA-targeting therapeutics, with a portfolio spanning 100+ companies and 20+ realized IPOs across NASDAQ, the Hong Kong Stock Exchange, the ChiNext Board, and the STAR Market.

The firm is led by two partners: K. Chiang (Founding & Managing Partner, Wharton MBA, with 30+ years of VC experience from Morningside Family Office and A.T. Kearney) and Wei Cheng (Partner, Ph.D. from the University of Massachusetts Medical School, with 20+ years of biomedical R&D, BD, and investment experience). TF Capital's primary customer segments are early-stage biotech innovators (which receive capital, strategic support, and global partnership facilitation) and institutional fund investors/LPs (which provide fund capital). Revenue is generated through portfolio company exits — including IPOs and license-out transactions — and management fees on its disclosed $1B in AUM.

TF Capital's most distinguishing outcome is its dominance in China's cross-border biotech license-out market: across 2019–2023, portfolio companies generated $2.8B+ in upfronts from 25 deals with multinational pharmaceutical corporations; in 2023 TF Capital captured 5 of the Top 15 highest upfront payments in Chinese innovator drug license-outs; and in 2024, portfolio license-out upfronts accounted for 38% of China's total ($4.1B), including the Regor→Genentech ($850M), LaNova→MSD ($588M), and Cellular Biomedicine→J&J ($245M) transactions. The firm's headquarters is located at Unit 801, CPIC XINTIANDI TOWER 2, 288 Xizang Road (S), Shanghai, China.

Name

TF Capital

Legal name

TF Capital

Website

https://tfcapital.net

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

TF Capital (泰福资本) is a Shanghai-based, dual-currency venture capital firm specializing in early-stage biotech investments in China, managing $1B AUM across 100+ portfolio companies with 20+ IPOs and a dominant share of China's biotech license-out market.

Ownership category

akta.pro rank

Product category

Venture Capital — Early-Stage Biotech

NAICS

Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)

SIC

Investment Advice (6282)

akta.pro primary industry

Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)

Keywords

• Biotech venture capital
• Early-stage pharma investing
• License-out deal sourcing
• Biopharmaceutical investment
• Life sciences portfolio management

Headquarters

HQ city

Pudong

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Investment Returns and Management Fees: VC firm generates returns through capital appreciation of portfolio companies, exits via IPOs and M&A, and collects management fees from fund investors.

Go-to-market motion1 record

Distribution channels2 records

Core offering

TF Capital is a Shanghai-based dual-currency venture capital firm that invests in early-stage innovative biotech and pharmaceutical companies in China. It provides capital and full value-chain strategic support to portfolio companies from inception through IPO, leveraging proprietary deal sourcing and deep biopharmaceutical networks. The firm has built a portfolio of 100+ companies and generated over $2.8B in upfront payments from license-out deals with multinational corporations.

Product overview

TF Capital is a dual-currency venture capital firm specializing in early-stage biotech investment. Founded in Shanghai in 2014, the firm provides capital and strategic expertise to innovative biotech companies from inception to global impact. The firm does not offer discrete technology products or services; rather, it delivers investment products including proprietary deal sourcing, strategic partnership facilitation with listed companies, clinical experts, and investment funds, and full value-chain support for portfolio companies through to IPO and exit.

Differentiator

Problem solved

Functional benefit

Products and services

• TF Capital Early-Stage Biotech Venture Fund Dual-currency venture capital fund providing capital and full value-chain strategic support to early-stage biotech and pharmaceutical companies in China. Available to limited partners (institutional investors) as a committed-capital fund vehicle; deployed into portfolio companies as venture financing. Manages approximately $1B AUM and has invested in 100+ companies with 20+ IPOs achieved.

Quantifiable outcome

• $2.8B+ in upfronts generated from 25 license-out deals across 14 companies in 5 consecutive years with MNCs
• +5 more outcomes

Named customers9 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• ARCH Venture Partners: US-based early-stage biotech VC with a long track record of founding and exiting life sciences companies. Comparable in early-stage biotech sourcing and university/founder-relationship-driven model.
• Loyal Valley Capital: China-focused asset manager with a dedicated biotech/healthcare investment platform and active license-out pipeline. Directly comparable in mandate, scale and China healthcare focus.
• Qiming Venture Partners: Leading Shanghai-based VC with deep healthcare and biotech franchise. Co-led Vivatides' $54M Series A in which TF Capital participated, indicating directly overlapping deal flow and LP/market positioning.
• Highlight Capital: Healthcare and biotech-dedicated China investor that participated in Vivatides' Series A alongside TF Capital, signaling directly overlapping deal sourcing and similar China biotech VC mandate.
• OrbiMed: Global healthcare-dedicated investment firm with early-stage biotech activity, including exposure to China. Closely comparable in early-stage biotech focus and pharma partnership-driven exit model.
• Legend Capital: Established China-focused VC with significant biotech investments; TF Capital partner Wei Cheng previously held senior roles at affiliated Tsinghua Holdings Capital/LegendStar, indicating a closely comparable franchise with overlapping networks.
• Apricot Capital: China healthcare/biotech-focused investor and existing backer of Vivatides Therapeutics alongside TF Capital. Directly comparable as a co-investor in the same early-stage China biotech rounds.
• Atlas Venture: US-based early-stage biotech-focused VC that builds companies from inception with a strong pharma partnership exit model. Comparable in biotech-only mandate and pharma BD-driven value creation.

Broad incumbents

• Hillhouse Capital: Major China-rooted investment platform with material healthcare/biotech exposure across public and private markets. Comparable as a scaled incumbent in China biotech investing, though much broader in mandate.
• HongShan (formerly Sequoia China): One of the largest China-focused VCs with active healthcare/biotech investing and global exit capabilities. Comparable incumbent competitor for biotech founders, though broader in sector coverage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments61 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TF Capital